Navigation Links
VEGF Trap-Eye Phase 2 Wet AMD Results Reported at ARVO Annual,Meeting

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--May 9, 2007 - Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced positive results from several studies evaluating the VEGF Trap-Eye in the neovascular form of age-related macular degeneration (wet AMD) and diabetic macular edema (DME). These findings were presented this week at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO). The data reported at the meeting from a pre-planned interim analysis of a Phase 2 randomized study of the VEGF Trap-Eye in patients with wet AMD and a Phase 1 DME trial are available on the Regeneron website (www.regeneron.com on the Events page, under the Investor Relations heading).

"We are very encouraged by the preliminary observation in the Phase 2 wet AMD trial that the most intense dosing regimen studied, 2 milligrams delivered by intravitreal injection every 4 weeks, resulted in an average gain of more than 10 letters after 12 weeks of treatment," said George D. Yancopoulos, M.D., Ph.D., President of Regeneron Research Laboratories. "Perhaps equally important is that after receiving only a single dose of the VEGF Trap-Eye, patients on average had an improvement in the number of letters read both 8 and 12 weeks after treatment. Although significantly more clinical testing is required, the VEGF Trap-Eye may offer the potential to improve vision in patients with wet AMD with a regular dosing regimen that is less frequent than monthly."

Regeneron and Bayer HealthCare AG plan to initiate the VEGF Trap-Eye Phase 3 program in wet AMD in the third quarter of 2007. In the first Phase 3 trial, the companies currently plan to evaluate the VEGF Trap-Eye using 4 and 8 week dosing intervals in direct comparison with ranibizumab (Lucentis(R), a registered trademark of Genentech, Inc.) administered every 4 weeks according to its label. The companies are collaborating on the global development of the VE
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Positive Interim Phase 2 Data Reported for VEGF Trap-Eye in Age-Related Macular Degeneration
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: VEGF Trap Eye Phase Wet AMD Results Reported ARVO Annual Meeting
(Date:5/4/2015)... WHIPPANY, N.J. , May 4, 2015 ... agreement with Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) ... clinical development for the prevention of thrombosis. Under the ... in areas of high unmet medical need. As ... evaluate the therapeutic profile of ISIS-FXI Rx in ...
(Date:5/4/2015)...  CytRx Corporation (Nasdaq: CYTR ), a ... today announced an interim analysis from its two ... with either gemcitabine or ifosfamide. Both studies combine ... doses of aldoxorubicin. The combinations appear to be ... level of aldoxorubicin (170 mg/m2), impressive tumor responses ...
(Date:5/4/2015)... 4, 2015 Dyadic International, Inc. ("Dyadic") ... and proprietary technologies are used to develop, manufacture ... bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, ... results for quarter ending March 31, 2015 after ... will host a conference call that day at ...
Breaking Medicine Technology:Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 3CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 2CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 3CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 4CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 5CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 6CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 7Dyadic International To Announce First Quarter 2015 Financial Results and Host Conference Call On Thursday, May 14, 2015 2Dyadic International To Announce First Quarter 2015 Financial Results and Host Conference Call On Thursday, May 14, 2015 3
... YORK, Jan. 11, 2011 Reportlinker.com announces that ... its catalogue: Advanced Drug Delivery ... http://www.reportlinker.com/p0358466/Advanced-Drug-Delivery-Markets-Liposomes-Polymers-and-Monoclonal-Antibodies.html Drug delivery ... drug product formulations being discovered frequently. Advanced drug ...
... NEW YORK, Jan. 11, 2011 Reportlinker.com announces ... in its catalogue: Innovative Drug ... http://www.reportlinker.com/p0359990/Innovative-Drug-Discovery-in-Emerging-Markets.html Introduction Emerging markets ... pharmaceutical industry, but it has been unclear the ...
Cached Medicine Technology:Reportlinker Adds Advanced Drug Delivery Markets (Liposomes, Polymers and Monoclonal Antibodies) 2Reportlinker Adds Advanced Drug Delivery Markets (Liposomes, Polymers and Monoclonal Antibodies) 3Reportlinker Adds Innovative Drug Discovery in Emerging Markets 2Reportlinker Adds Innovative Drug Discovery in Emerging Markets 3
(Date:5/4/2015)... Greifensee, Switzerland (PRWEB) May 04, 2015 ... entitled “ The Importance of Data Integrity in ... Bob McDowall as guest presenter. This webinar will ... EDT (15:00 GMT). , Data integrity is a ... information submitted to regulatory agencies. However, in recent ...
(Date:5/4/2015)... 04, 2015 Ticket Down is a reputable ... Cup (ICC) . While the World Cup is the ... every four years, the International Champions Cup is one of ... the all-time attendance record for soccer in the United States ... House at the University of Michigan. This year, the defending ...
(Date:5/4/2015)... May 04, 2015 Los Angeles ... offering a more comfortable and attractive alternative for patients ... choice for those who have lost teeth. Unfortunately, they ... insecure or slip at the worst possible moment and ... talks. They can also painfully pinch or rub gums, ...
(Date:5/4/2015)... Chicago, Ill., (PRWEB) May 04, 2015 ... the American Brain Tumor Association (ABTA) show that people ... their diagnosis and treatment options, including clinical trials, at ... of days to make difficult decisions about their course ... the launch of the first nationwide brain tumor volunteer ...
(Date:5/4/2015)... San Diego, CA (PRWEB) May 04, 2015 ... hosted a ribbon cutting ceremony at their brand new, ... of this year. The new building will not only ... patient population, but will also offer community and educational ... , The new facility is located next door to ...
Breaking Medicine News(10 mins):Health News:METTLER TOLEDO Announces Live Webinar on the Importance of Data Integrity in a GXP Regulated Laboratory 2Health News:Cheap 2015 International Champions Cup (ICC) Tickets: Ticket Down Slashes Ticket Prices on International Champions Cup (ICC) Presale Tickets 2Health News:Cheap 2015 International Champions Cup (ICC) Tickets: Ticket Down Slashes Ticket Prices on International Champions Cup (ICC) Presale Tickets 3Health News:Cheap 2015 International Champions Cup (ICC) Tickets: Ticket Down Slashes Ticket Prices on International Champions Cup (ICC) Presale Tickets 4Health News:Los Angeles Dental Implants Doctor, Kevin Sands DDS, Now Offers a More Comfortable and Aesthetically-Pleasing Solution to Denture-Wearers 2Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 2Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 3Health News:San Diego Fertility Center Hosted a Ribbon Cutting Ceremony at Its New, Expanded Facility 2Health News:San Diego Fertility Center Hosted a Ribbon Cutting Ceremony at Its New, Expanded Facility 3
... in Australia have called upon the federal government to ... from war in Iraq and Afghanistan. ,Doctor Robert ... War says there needs to be a specific counseling ... ,He says the lack of services and ...
... a chemotherapy drug has recently been tested in ... and found //to have significant improvement in Progression-Free ... on Phase III trial on Satraplatin has shown: ... Improvement in Progression-Free Survival ,* ...
... has information about outbreak of Avian Influenza in ... outbreaks in Pakistan, the North-Western States bordering Pakistan ... bordering areas especially to check informal/illegal trade of ... surveillance especially of poultry and in areas visited ...
... get married is a waste of breath, a US expert ... // ,William Smith, the vice president of the Sexuality, ... a six-year study commissioned by the US Congress found that ... on pushing sexual abstinence outside marriage had had no discernible ...
... on a young woman, an Australian man gouged out both her ... to be the 28-year-old woman's partner, a man of around 30 ... the incident. ,The horrific string of events began ... of a Victorian country town- Malmsbury, 100 km northwest of Melbourne. ...
... Indiana legislators in the US have decided on raising tax ... ,As per a deal agreed upon on Sunday, the ... pack and the expected additional flow to the treasury, of ... fund several health programs. ,Most of the tax ...
Cached Medicine News:Health News:Row in Australia Over Mental Health Support Available for Returning Soldiers 2Health News:Satraplatin Benefits Hormone Refractory Prostate Cancer Patients 2Health News:Satraplatin Benefits Hormone Refractory Prostate Cancer Patients 3Health News:Satraplatin Benefits Hormone Refractory Prostate Cancer Patients 4Health News:Satraplatin Benefits Hormone Refractory Prostate Cancer Patients 5Health News:Steps To Prevent Out-Break Of Bird Flu 2Health News:Steps To Prevent Out-Break Of Bird Flu 3Health News:Smokers to Be Taxed to Fund Healthcare for Uninsured 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: